AskAt Inc. received a notice of allowance from the U.S. Patent Office of a use patent for its EP4 receptor antagonist in immuno-oncology therapy (Appl. No. 16/385,524). AskAt and Arrys Therapeutics, a wholly owned subsidiary of Ikena Oncology ((NASDAQ: IKNA) headquartered in Boston, Massachusetts), jointly filed the patent application. The patent will remain effective until April 15, 2039.